Condition

NMO Spectrum Disorder (NMOSD) (2)

Neuromyelitis Optica (NMO) (2)

Overall Status

Completed (2)

Sign in for free

Phase

phase 3 (2)

Sponsor

Hoffmann-La Roche (2)

Collaborator

Chugai Pharmaceutical (2)

Intervention

placebo (2)

satralizumab (2)

baseline treatment (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

neuromyelitis optica (nmo)

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD) Trial in Worldwide (Satralizumab, Placebo)

Completed

Neuromyelitis Optica (NMO)
NMO Spectrum Disorder (NMOSD)

Satralizumab
Placebo

Aurora, Colorado
+57 more

Feb 11, 2022

Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD) Trial in Worldwide (Satralizumab, Placebo, Baseline Treatment)

Completed

Neuromyelitis Optica (NMO)
NMO Spectrum Disorder (NMOSD)

Satralizumab
+2 more

Birmingham, Alabama
+38 more

Jan 24, 2022